Latest Intellectual Property News

Bod Science Limited reports a positive cash flow quarter driven by customer receipts, an R&D tax incentive, and proceeds from intellectual property sales, while navigating its Deed of Company Arrangement.

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.

Sunrise Energy Metals reports strong high-grade scandium drill results at Syerston and secures $7.5 million to accelerate project development. The company is updating its feasibility study amid growing market demand and geopolitical supply pressures.

Linius Technologies has landed a paid Proof of Concept with a leading European soccer league, aiming to showcase its video search and assembly platform to boost fan engagement. This deal could open doors to significant Tier 1 contracts in the lucrative European football market.

PlaySide Studios has released its unaudited FY25 results, showing revenues just below guidance and an EBITDA loss within expectations amid restructuring. The company remains optimistic about revenue growth and cost savings in FY26, pending the launch of its new title.

Firebird Metals has secured two key patents for its proprietary Lithium Manganese Iron Phosphate (LMFP) battery materials, reinforcing its position in the emerging $20 billion LMFP market. The company’s integrated production approach and expanding IP portfolio set the stage for global growth amid shifting technology controls.

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.

PIES Holding Co and Activeport Group have launched a strategic joint venture to integrate AI-driven low-code/no-code tools with advanced network orchestration software, aiming to transform telecommunications and data centre operations globally.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Ava Risk Group reports a 5% revenue increase and a positive EBITDA turnaround in FY25, underpinned by its advanced security technologies. The company eyes over $88 million in FY26 sales opportunities despite some project delays.

X2M Connect Limited has announced a non-renounceable entitlement offer to raise approximately $2.26 million, issuing new shares and options to eligible shareholders. The capital raise aims to strengthen the company’s balance sheet and support AI platform enhancements and market expansion.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.